Fig. 7: Analyses of CD8 expression using immunohistochemistry (IHC, n = 149) or RNA-seq (n = 253) across cohorts included in COMPASS.
From: Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Boxplots in Panel B–F depict 1st quartile, median and 3rd quartile +/− 1.5 interquartile range. P-values derived from two-sided statistical tests. A Spearman correlation of CD8 IHC vs RNA-seq expression. B Comparison of CD8 IHC expression in primary biopsy sites vs metastatic sites. C CD8 expression according to specific KRAS mutation Left) analysis by IHC Right) analysis by RNA-seq. D CD8 expression (RNA-seq) in HRDetect hi vs lo cases. E CD8 expression according to Moffitt subtype (basal-like vs classical) in liver metastases Left) analysis by IHC, Right) analysis by RNA-seq. F CD8 expression by IHC in liver metastases comparing GRIm-S lo vs hi.
